There are limited data on the quality of treated blood pressure (BP) control during normal daily life, and in particular, the prevalence of 'masked uncontrolled hypertension' (MUCH) in people with treated and seemingly well-controlled BP is unknown. This is important because masked hypertension in 'treatment naïve' patients is associated with a high risk of cardiovascular events. We therefore conducted the first study to define the prevalence and characteristics of MUCH among a large sample of hypertensive patients in routine clinical practice in whom BP was treated and controlled to recommended clinic BP goals.
Introduction
Masked hypertension (MH) is a term used to define people who have a normal seated clinic blood pressure (BP) but an elevated out-of-office BP, as determined by ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM). Masked hypertension is the opposite of the more commonly recognized 'white coat hypertension'. Patients with MH are now known to be at particularly high risk of developing cardiovascular disease (CVD) because they often remain undetected and untreated. 1, 2 Most studies on the prevalence of MH have primarily focused on 'treatment naïve' patients, prior to the diagnosis of hypertension, and many of them based the measurements on HBPM or daytime ABPM, or were of small size. 2,3 -10 This daytime definition of MH would not include people whose sole abnormality is an elevation in nocturnal BP, which some studies suggest is the strongest predictor of CVD risk compared with daytime or 24-h mean pressures. 11 -13 Furthermore, few studies have established the prevalence of the equivalent of MH, i.e. 'masked uncontrolled hypertension', which we have termed MUCH, in patients with treated hypertension. We use MUCH to describe treated patients in whom BP levels are suboptimally controlled according to ABPM, but who are considered controlled to clinic BP targets by current treatment guidelines recommendations (,140/90 mmHg), which universally recommend the use of seated clinic BP to monitor BP control. 14 -16 MUCH has gone unrecognized because few studies have used 24-h ABPM 8, 17 to determine the prevalence of suboptimal BP control in seemingly well-treated patients, and there are no such studies in large cohorts of treated patients attending usual clinical practice. The normal range for ABPM values has been defined based on data from prospective studies. 14,18 -20 For the diagnosis of hypertension, the recent UK NICE guidelines 15 defined a daytime mean ABPM of ≥135/85 mmHg as being equivalent to the usual seated clinic BP threshold of ≥140/90 mmHg. However, ABPM also yields values for nocturnal pressures, and previous studies have suggested an ABPM-based diagnostic threshold for nocturnal hypertension as ≥120/70 and ≥130/80 mmHg for the 24-h BP average. 14, 18, 19 Despite the recognized potential for clinic BP alone to both overand underdiagnose hypertension, to date, no guidelines have recommended the routine use of ABPM to monitor the quality of BP control because there are very little data on the quality of BP control in routine clinical practice.
The Spanish ABPM registry 21, 22 was established to evaluate the utility of the wider use of ABPM, and we have used this large, wellcharacterized population of hypertensive patients specifically to determine the frequency of MUCH in patients with treated hypertension. To our knowledge, this is the first large-scale study to evaluate and report the prevalence and characteristics of MUCH in people with seemingly well-treated hypertension.
Methods

Study design and participants
The Spanish ABPM Registry was established by the distribution of .1000 ambulatory BP monitors (Spacelabs90207, Spacelabs, Inc., Redmond, WA, USA) for routine use by primary care physicians and physicians from specialist units across Spain. Details of physicians' recruitment and characteristics of the registry have been previously reported. 13, 21, 22 Briefly, physicians and nurses received training in the use of ABPM. The data from the ABPM device and the corresponding medical charts were linked via an Internet-based platform to ABPM registries, enabling physicians to receive ABPM reports in real time, and these registries were stored in the database of an external clinical research organization. Consistency and quality of the information is centrally checked through the platform and using protocolized actions. International practice guidelines were used to establish general indications for ABPM. 14, 18, 19 The registry continues to expand and has received data from 1500 patients per 
Blood pressure measurements
Blood pressure was measured at the clinic with a calibrated mercury sphygmomanometer or a validated semi-automatic oscillometric device, after 5 min of rest in a sitting position. Clinic BP values were calculated as the mean of two readings. Thereafter, 24-h ABPM was performed using an automated non-invasive oscillometric device (SpaceLabs 90207), programmed to register BP at 20-min intervals for the 24-h period. Appropriate cuff sizes were used. The ABPM recordings were performed on working days and the patients were instructed to maintain their usual activities, and to keep the arm extended and immobile at the time of each cuff inflation. Valid ABPM recordings had to fulfil a series of pre-established criteria, including successful recording of ≥80% of systolic BP (SBP) and diastolic BP (DBP) during both the daytime and nocturnal periods, and at least one BP measurement per hour. Daytime and nocturnal periods were defined according to the patient's self-reported data of going-to-bed and waking times.
Study variables
Variables collected for each patient were based on interviews and physical examination at the time of visit and on data drawn from clinical records and defined and measured in accordance with international guidelines. 14 High prevalence of masked uncontrolled hypertension
Patients with MUCH were classified according to whether they presented only-daytime BP elevated (threshold ≥135/85 mmHg), 14, 18, 19 only-nocturnal BP elevated (threshold ≥120/70 mmHg), 14, 18, 19 or both. The first two groups were compared using the Pearson x 2 test.
Since the reproducibility of ABPM data has been poorly studied, 24 and could have affected the reliability of the reported prevalence of MUCH, we also examined the reproducibility of MUCH and MUCH subtypes in a sample of patients who underwent a second ABPM, using the x 2 test and linear kappa coefficient for testing agreement between both sessions. Logistic regression analysis was used to assess factors independently associated with the following outcomes: MUCH ( vs. both clinic and 24-h BP controlled), and isolated nocturnal MUCH (vs. isolated daytime MUCH). Covariates included age, gender, hypertension duration, cardiovascular risk factors (BMI, obesity, smoking, diabetes, total and LDL cholesterol, triglycerides, creatinine), TOD (LVH, UAE, carotid plaque, and TOD as a whole), CVD risk, previous CVD, renal disease, number of anti-hypertensive drugs used (1 vs. 2 or more), clinic SBP and DBP, and 24-h SBP and DBP. All variables were modelled as categorical (dichotomous) except age, BMI, hypertension duration, blood cholesterol, triglycerides, creatinine, UAE, and BP (continuous). Factors with significance at P ≤ 0.20 in univariate analyses (Wald x 2 test) were introduced into a multivariable logistic regression model using the stepwise forward method for variable selection. Then, with the variables selected and those that were considered clinically relevant, a final model was fitted. Goodness-of-fit of models was evaluated with the Hosmer -Lemeshow test. We excluded 'CV risk' 14 as a covariate in multivariable analyses because it showed co-linearity with other covariates and impeded robust modelling. The SPSS for Windows version 19.0 software was used for statistical analysis.
Results
Sample characteristics
There were 4608 patients with MUCH despite optimal clinic BP control (mean age 59.4 years, 59.7% men), and 10 232 patients were identified as having optimal BP control, i.e. with both office and 24-h BP controlled. When compared with the optimal BP control group, MUCH patients were more likely to be male and had a worse CVD risk profile, including higher proportion of smokers, diabetes, higher levels of triglycerides, greater proportion of high estimated CVD risk, and marginally but not significantly higher levels of LDL cholesterol (P ¼ 0.06) and higher proportion of TOD (P ¼ 0.09) ( Table 1) . The percentage of MUCH receiving monotherapy did not significantly differ from those optimally controlled ( Table 1) . Most MUCH patients took their anti-hypertensive medication only in the morning (76.6 vs. 76.2% in those optimally controlled), 12.5% only in the evening/night, and 10.9% in both the morning and the evening/night. The percentage of MUCH vs. optimal control patients taking specific drug classes were diuretics 7.6 and 8%, respectively (P ¼ 0.594), beta-blockers 12.1 and 17.2% (P , 0.01), angiotensin- converting enzyme inhibitors (ACEi) 25.5 and 24.7% (P ¼ 0.541), angiotensin-receptor blockers (ARB) 19.9 and 19.8% (P ¼ 0.932), calcium-channel blockers 9.6 and 6.5% (P , 0.01), and alphablockers 1.4 and 1.1% (P ¼ 0.327). Mean daytime and nocturnal ambulatory BP were higher in those with MUCH when compared with the optimal control group ( Table 2 ). The absolute difference in nocturnal SBP between both groups was 17.4 mmHg (126.8 vs. 109.4 mmHg, respectively), and 17.8 mmHg in daytime SBP (136.5 vs. 118.7 mmHg, respectively). The corresponding absolute difference in DBP was 10 mmHg for both daytime and nocturnal BP ( Table 2) .
Prevalence of masked uncontrolled hypertension
The proportion of MUCH among treated hypertensive patients well controlled in the clinic was 31.1% (95% confidence interval 30.4-31.8%). The prevalence of MUCH was significantly higher in males, patients aged ,65 years, smokers, those with diabetes, or those at high cardiovascular risk than their counterparts (Table 3) . However, the difference in the prevalence of MUCH according to obesity status, TOD, or previous CVD were only marginally significant or not clinically relevant (absolute differences ,4 mmHg). Notably, the prevalence of MUCH was clearly higher when the clinic BP was closer to the BP control threshold, i.e. in those with borderline control according to clinic BP ( Table 3) .
The prevalence of MUCH was not significantly different between patients on one drug vs. those on ≥2 drugs (31.7 vs. 30.6%, P ¼ 0.151), and either according to the time of drug administration ( Table 3) . Lastly, the prevalence of MUCH was significantly lower in patients taking only beta-blockers (24.6%) and higher in those on only calcium-channel blockers (40.8%) or only alpha-blockers (37.1%) ( Table 3 
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Contribution of elevated daytime and nocturnal blood pressure to masked uncontrolled hypertension
Although 60% of MUCH patients had both uncontrolled daytime and nocturnal BP, the proportion of patients with only-nocturnal BP elevated was almost double than that with only-daytime elevated BP (24.3 vs. 12.9%; P , 0.001) ( Table 4) . A few (126 or 2.7%) of the patients with MUCH had both daytime and nocturnal BP controlled, but they all had a mean 24-h BP .130/80 mmHg.
Reproducibility of masked uncontrolled hypertension
In 231 patients with treated hypertension and MUCH, two ABPM recordings were available, separated by a median time between the two visits of 1 month (inter-quartile range 0.5 -8 months). Of these, 202 (87.4%; 95% confidence interval, 83.5-91.5%) continued to fulfil the criteria for MUCH in the second ABPM session, and all of the 66 patients with a third ABPM available persisted as MUCH patients. Consequently, the concordance in the prevalence of MUCH between the two ABPM sessions was very good (k ¼ 0.85). Furthermore, no statistically significant differences in the prevalence of MUCH subtypes were observed between ABPM sessions 1 and 2 (P ¼ 0.913). Moreover, the MUCH classification remained unchanged in 58 of 63 (92.1%) with only-nocturnal MUCH, 23 of 29 (79.3%) with only-daytime MUCH, and 116 of 133(87.2%) of those with daytime-nocturnal MUCH (Figure 1) . The clinical characteristics of the small reproducibility sample (mean age, 57.9 years; mean BMI, 29 kg/m 2 ; median duration since hypertension diagnosis, 3 years; and CVD risk, 41.6%) resembled those of the total 4608 patients with MUCH (Table 1) . Likewise, the distribution of MUCH subtype in both samples was quite similar: 27.3 and 24.3%, respectively, had a nocturnal-MUCH subtype, and 12.6 and 12.9% had a daytime subtype ( Table 4 and Figure 1 ).
Multivariable analyses of MUCH
The multivariable odds ratio of having MUCH in people with treated and well-controlled clinic BP was significantly inversely related to age, and higher in males, those with a longer duration of hypertension, obesity, smokers, those with diabetes, and in those with a clinic BP closer to the control threshold (140/90 mmHg) ( Table 5 ; goodness-of-fit Hosmer-Lemeshow, P ¼ 0.109). In addition, the odds of having only-nocturnal MUCH was significantly higher among older patients, those with obesity, TOD or previous CVD than in patients with only-daytime MUCH (odds ratios of 1.031, 1.570, 1.863, and 1.969, respectively; all P , 0.01), and marginally but not significantly higher in patients with diabetes (OR 1.33; 95% CI 0.94-1.65, P ¼ 0.10).
Discussion
The results of this study suggest that almost one-third of people who are considered to have adequate BP control by conventional clinic criteria do not have their BP controlled when assessed by ABPM. We have used the term 'masked uncontrolled hypertension' or 'MUCH' to describe this cohort of patients. Importantly, over one in three patients with borderline clinic BP have MUCH and therefore have a BP that is not adequately controlled. The frequency of MUCH was especially high in patients with major cardiometabolic risk factors or who smoke, all of which identify people who are at higher CVD risk who would benefit most from optimal BP control.
These findings were observed in a large European population of people cared for in usual clinical practice, and the prevalence of MUCH was consistent across the status of cardiovascular risk factors, TOD, CVD, and anti-hypertensive medication. Our results also suggest a good short-term reproducibility of MUCH as defined by ABPM, which adds to the scarce literature on the reproducibility of ABPM-defined MH. 24 Moreover, our results suggest a good reproducibility of nocturnal and daytime MUCH subtypes. We did not analyse possible changes in treatment over time in these analyses; however, the median time between the two visits was only 1 month and thus treatment changes were unlikely. Thus, our findings suggest that based on the currently recommended use of clinic BP to monitor BP control, physicians will substantially overestimate the number of patients who are truly controlled, leaving many higher-risk patients at excess risk.
Importance of nocturnal masked uncontrolled hypertension
We found that suboptimal nocturnal BP control accounted for more cases of MUCH than suboptimal daytime BP control. Indeed, about one-quarter of MUCH cases had only the nocturnal BP elevated (vs. 13% with elevated daytime BP). Remarkably, nocturnal SBP/DBP was almost 20/10 mmHg higher in MUCH patients when compared with those patients in whom both clinic BP and ABPM readings were controlled. Such difference seems to be too high to be explained by methodological aspects of ABPM measurement (e.g. frequent inflation of the cuff). We speculate that the predominance of nocturnal MUCH could be related to some physiological mechanisms involving sympathetic activity and sleep apnoea. 25, 26 Moreover, we found the classification of nocturnal MUCH to be reproducible in the short term, and that factors related to older age, obesity, diabetes, TOD, and the presence of CVD might play a role, as they were significantly associated with isolated elevation of nocturnal BP. However, further research is clearly needed. Whatever the explanation, the fact that MUCH is most often because of nocturnal hypertension is important because nocturnal BP has been strongly linked to CVD morbidity and mortality and nocturnal hypertension can only be detected by ABPM. 14,18 -20 Comparison with other studies
The frequency of MH in HBPM studies ranges from 9 to 37%, and 9 to 21% based on ABPM. 6 However, HBPM cannot properly assess BP during sleep, and nocturnal BP is a stronger risk factor for TOD and CVD. 11 -13 This does not mean that HBPM is not a valid alternative to ABPM in the diagnosis of MH, and some authors have indicated that both ABPM and HBPM appear to be appropriate for the detection of MH. 27 But the fact remains that daytime BP measurements alone are insufficient to detect all MH cases. In untreated hypertensive patients, the prevalence of MH ranges from 9 to 14%. 6 Interestingly, in our untreated patients the prevalence of MH was 33.6%, a quite similar proportion to that of MUCH. But in general in patients with treated hypertension, the prevalence is less known. The present study thus adds new evidence on the importance of MUCH, particularly nocturnal-MUCH in a large population of already treated hypertensive patients attended in clinical practice. We did not find any significant association between the number of drugs taken and the prevalence of MUCH, consistent with some studies, 9 but at odds with others. 10 We found no statistically significant or clinically relevant associations between MUCH and time of drug administration either. Nevertheless, it cannot be ruled out that redistribution of the time of anti-hypertensive drug therapy would improve BP control, thus reducing the prevalence of MUCH and CVD risk. Interestingly, the frequency of MUCH appeared higher in those receiving calcium-channel blockers, but we caution against reading too much into this because this could be confounding by indication. Indeed, it should be noted that this is not a randomized clinical trial, but an observational registry, and thus results concerning the type and timing of anti-hypertensive medication related to MUCH must be interpreted with caution. New studies done in adequately selected patients randomized to different drug-treatment schedules would help address this issue more properly. Finally, irrespective of the type or timing of treatment, the clinic BP was controlled in these patients and therefore the physician would have been content with the existing treatment.
Clinical profile of MUCH patients
The demographic and clinical characteristics of patients with MH and MUCH are poorly defined, 2 indeed, no large study has ever previously focused on patients with MUCH. Available 24-h ABPM-based studies have identified high-normal clinic BP, age, smoking, obesity, diabetes, proteinuria, and high CVD risk associated with MH. 3 -6,28 We have identified the clinical profile of MUCH patients as more likely to be male or obese, smokers, or those with diabetes. Unfortunately, pathophysiological mechanisms responsible for MH are still unknown. Nevertheless, it is notable that clinic heart rate was marginally higher in MUCH patients than in controlled patients (73.2 and 72.6 b.p.m., respectively, P ¼ 0.009), and in particular there was a statistical trend in MUCH patients with diabetes (74.2 vs. 73.3, P ¼ 0.08). This may suggest an increased sympathetic activity in some patients with MUCH, consistent with findings reported in detail by Grassi et al.
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Clinical and public health implications
Since over one-third of the patients with borderline clinic BP control have MUCH, currently recommended methods of BP measurement seem to be insufficient to manage such patients with treated hypertension, and therefore primary care physicians should consider the more routine use of ABPM in patients with borderline clinic BP. At the very least, those with borderline clinic BP and high CVD risk should be considered for ABPM.
Defining patients with MUCH could have important public health implications because this represents millions of people at a population level and such patients are more likely to have major CVD risk factors and have the most to gain in absolute terms with regard to benefits from improved BP control. Although the prognosis for MUCH is presently unknown, it is well recognized that its counterpart, i.e. MH in seemingly normotensive untreated patients is associated with a poor prognosis. 1, 2, 6, 7, 29 Study strengths and limitations A key strength of this study is that it was performed on a large nationwide population sample-the first time that the prevalence of MUCH has been assessed in such a large single cohort of hypertensive patients (62 788 treated and 14 840 with a treated clinic BP ,140/90 mmHg). Even though any registry study has inherent potential sources of bias associated, and there may be some selection bias from inclusion criteria for conventional ABPM indications, it is important to note that Spanish ABPM registry provides a real-world view of clinical practice, at scale, for several reasons: (i) both primary care physicians and specialist referral units were represented, (ii) physicians and patients were recruited across the 17 autonomous communities covered by the national healthcare system in Spain, and (iii) 90% of treated and controlled hypertensive patients in Spain have a BP 130 -9/85 -9 mmHg or were at high added risk according to European guidelines, 14, 30 situations that were consistent with clinical indications for ABPM as defined by the Registry. Thus, the registry used here was very inclusive. The current study must be interpreted within the context of its potential limitations: (i) 'normal clinic BP' was based on the recording of only two seated clinic BP measurements at a single visit. Nevertheless, in a study of HBPM with treated hypertensive patients, no variation in the frequency of MH was observed with the number of clinical measurements (three or six); 31 (ii) the BP levels we chose for defining normality in ambulatory BP are those most commonly used and evidence-based, 14, 15 but possibly conservative and may change in the future. Lower BP thresholds, such as the recently proposed population-based outcome-driven thresholds 32 would yield an even greater prevalence of MUCH than that we have reported here; (iii) the multivariable regression model was intended only to identify factors independently associated with MUCH, and their results should be interpreted with caution; (iv) we have no way of assessing patients' concordance with their anti-hypertensive treatment; and (v) pulse wave velocity, maybe the most important marker of TOD regarding risk prediction, 33 was not included in this study. Nevertheless, it could be helpful in future work to evaluate potential mechanisms for our findings.
Conclusions
In conclusion, MUCH in people with seemingly well-controlled clinic BP is high and seems to be reproducible on repeat ABPM measures.
The characteristics of such patients (male, longer duration of hypertension, obesity, smoking history, and diabetes) indicates that this is a higher-risk group with most to gain from improved BP. An important determinant of MUCH is poorer control of nocturnal BP, which can never be appreciated from clinic readings alone. Moreover, nocturnal BP is increasingly recognized as a strong predictor of risk in many studies of ABPM. Thus, the present study suggests that reliance on clinic BP alone is often inadequate to optimize BP control because many patients (especially higher-risk patients), have an elevated nocturnal BP. Our data suggest that ABPM should be used more widely to monitor BP control, especially in higher-risk groups. However, further studies that assess the impact of such a strategy on clinical outcomes and define the cost-effectiveness of such an approach are needed.
